Immunohistochemistry expression of CDK4, MDM2, ±-catenin, IMP3 and amphiregulin in encondromas and central condrosarcomas with clinical-evolutive correlation

• Grant number: 19/00402-8
• Support Opportunities: Regular Research Grants
• Start date: August 01, 2019
• End date: July 31, 2021
• Field of knowledge: Health Sciences - Medicine - Pathological Anatomy and Clinical Pathology
• Principal Investigator: Eliane Maria Ingrid Amstalden
• Grantee: Eliane Maria Ingrid Amstalden
• Host Institution: Faculdade de Ciências Médicas (FCM). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil

Abstract

Chondrosarcomas are a heterogeneous group of malignant cartilaginous tumors with diverse clinical, radiological and morphological manifestations. The vast majority are represented by Conventional Chondrosarcoma (CC) (90%) and are histologically subdivided into grades I, II and III. Distinguishing CC Grade I from Enchondromas is a diagnostic challenge and of fundamental importance for the treatment and prognosis. Some pathways of oncogenic signaling have been implicated in the biology of tumor progression of cartilaginous neoplasms such as those related to the cell cycle (CDK4, MDM2, and ²-catenin) and to cell migration (IMP3 and Anfiregulin). These pathways are not fully elucidated in cartilaginous tumors. The present study proposes to evaluate the immunohistochemical expression of the proteins: CDK4, MDM2, ²-catenin, IMP3, Anfiregulina in Enchondromas and Conventional Central Chondrosarcomas, through an immunohistochemical study, correlating: histological grade, clinical and prognostic data. A retrospective study will be carried out with a survey of approximately 100 cases of cartilaginous tumors with diagnosis of Enchondroma or Conventional Central Chondrosarcoma filed at the HC / Unicamp Pathology Service in the period 1986-2016, as well as the analysis of clinical and evolutionary data obtained from medical records. Histological and immunohistochemical studies will be performed with qualitative and quantitative analyzes according to Zhu and collaborators, 2013. The obtained data will be submitted to statistical tests. It is expected that the results allow: to distinguish CC Grade I from Enchondromas; to establish possible pathways of tumor pathogenesis and progression in these neoplasias and to allow new therapeutic possibilities for these neoplasias. (AU)